002630 — Orient Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual income statement for Orient Bio, fiscal year end - March 31st, KRW millions except per share, conversion factor applied.

	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	25,180	26,276	28,819	28,005	29,398
Cost of Revenue
Gross Profit	6,196	9,014	9,824	9,584	7,197
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	35,404	31,668	27,566	28,651	32,474
Operating Profit	-10,224	-5,392	1,253	-646	-3,076
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-22,490	-3,361	-12,591	12,871	-13,195
Provision for Income Taxes
Net Income After Taxes	-22,455	-3,430	-12,424	12,871	-13,195
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-15,634	34,198	-12,424	12,871	-13,195
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-15,634	34,198	-12,424	12,871	-13,195
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-169	-20.1	-104	108	-111
Dividends per Share